Morgan Ebert, Executive Editor

Get caught up with Contemporary Pediatrics. This list helps you navigate our top stories from the week, all in one place.

A CHOP-led study identified IL-6 and IFN-γ immune activation tied to worse recovery in children with sepsis or organ failure.

A first-in-human study of 96 preterm infants shows broadband optical spectroscopy can safely distinguish NEC from healthy tissue within 2 minutes at bedside, without pain or radiation.

New ADA 2026 analyses show Afrezza delivered comparable glycemic control, favorable safety, and higher treatment satisfaction in youth.

The FDA has approved expanded indications for tocilizumab-bavi (TOFIDENCE), adding severe or life-threatening CAR T-cell–induced CRS and hospitalized COVID-19 in patients aged 2 years and older.

The FDA has accepted Takeda's supplemental application for IV vedolizumab in patients ages 2 and older with moderate-to-severe UC or Crohn's disease, with a PDUFA date set for Q1 2027.

The FDA has approved an every-8-week maintenance regimen for lebrikizumab-lbkz (EBGLYSS), giving eligible adults and adolescents with moderate-to-severe atopic dermatitis as few as 6 injections per year without mandatory topical therapy.

The FDA has approved bemotrizinol as the first new active sunscreen ingredient under the OTC monograph in nearly two decades, clearing the broad-spectrum UV filter for use in adults and children 6 months of age and older.

FDA designations for investigational GEn-1123 may support development in Duchenne muscular dystrophy, but clinical data remain limited.

New research using a natural experiment design found consistent reductions in diagnosed influenza among vaccinated young children in every season studied from 2016 to 2023.

Vertex reported phase 3 ALYFTREK data in children aged 2 to 5 years with cystic fibrosis and responsive CFTR genotypes.

A cross-sectional study comparing 2 Australian population-based cohorts found that updated infant feeding guidelines recommending egg introduction by 6 months were associated with a 17.7% relative reduction in egg allergy prevalence.

The FDA has broadened the approved indication for marstacimab (Hympavzi; Pfizer) to include pediatric patients ages 6–11 with hemophilia A or B and patients 12 and older with inhibitors.

A look back at the latest clinical trial updates for the pediatric population during May 2026.

Common pediatric skin infections are often managed in primary care, but some presentations require dermatology referral and further evaluation.

Take a quick look at everything you may have missed in May, including the top FDA approvals and latest clinical updates.

FDA approved ensitrelvir for COVID-19 post-exposure prophylaxis in patients aged 12 years and older after positive phase 3 trial results.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from May 2026.

The FDA accepted an sNDA for mavacamten in adolescents with obstructive hypertrophic cardiomyopathy, with a decision expected in September 2026.

This decision marks the first FDA-approved inhaled insulin for pediatric patients.

The FDA extended its review of adrabetadex for infantile-onset Niemann-Pick disease type C to November 17, 2026, after a major NDA amendment.

FDA expanded approval of linaclotide for functional constipation to include children aged 2 to 5 years.

New AAP guidance calls for transparent pay practices and family-friendly policies to address gender-based pay inequities in pediatrics.

FDA approval moves adapalene 0.1% and benzoyl peroxide 2.5% gel to OTC use for acne in patients aged 12 years and older.

Ecopipam lowered relapse risk in pediatric Tourette syndrome responders in phase 3 data supporting a planned FDA submission.

Adolescents spent an average of 50 minutes on smartphones during school nights, with social media accounting for most use.

French data suggest dual RSV immunization with RSVpreF and nirsevimab was associated with low infant RSV hospitalization rates.

Phase 3 data showed vosoritide significantly improved annualized growth velocity and height outcomes in children with hypochondroplasia.

FDA accepted a levacetylleucine sNDA for ataxia-telangiectasia and set a September 19, 2026, target action date.

Early phase 2 data suggest zovegalisib may reduce lesion volume and improve symptoms in PIK3CA-driven vascular anomalies.